Avecho Biotechnology Limited (AU:AVE)
ASX:AVE
Want to see AU:AVE full AI Analyst Report?
AVE Stock Chart & Stats
AU$0.01
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.01
AU$0.00(0.00%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.01
Previous CloseN/A
Volume188.16K
Average Volume (3M)N/A
Market Cap
AU$45.97M
Enterprise ValueAU$30.96M
Total Cash (Recent Filing)AU$4.66M
Total Debt (Recent Filing)AU$14.47K
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding3,830,448,200
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)18.85
Price to Sales (P/S)23.75
P/FCF Ratio26.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue MomentumAccelerating revenue in 2025 indicates improving product adoption and market traction for Avecho's TPM platform. Over the next 2–6 months sustained top-line momentum can improve operating leverage, support investment in commercialization, and reduce near-term reliance on external funding if maintained.
Positive Cash GenerationThe swing to positive operating and free cash flow in 2025 provides a durable improvement in internal funding capacity. Consistent cash generation reduces immediate refinancing risk, supports ongoing R&D or partner programs, and creates a base to fund commercialization steps if cash flows remain stable.
Low Financial LeverageVery low debt levels give Avecho strategic flexibility to fund development, enter partnerships, or respond to setbacks without heavy interest burdens. This durable balance-sheet strength moderates downside risk and preserves capacity to invest in commercialisation or licensing initiatives over the coming months.
Bears Say
Persistent Losses & Shrinking EquityOngoing sizable operating and net losses that have eroded equity create a structural risk to shareholder value and financing flexibility. If losses persist, management may need to raise capital or dilute shareholders, impairing the firm's ability to execute long-term commercial strategies without sustained profit improvements.
Cash Flow VolatilityLarge year-to-year swings in free cash flow signal operational and working-capital sensitivity. This volatility complicates multi-quarter planning for R&D and partnerships, and raises the probability that positive 2025 cash flows may not persist absent more predictable revenue streams or structural margin improvements.
Unclear Monetisation & Partnership VisibilityA monetisation model reliant on licensing, partnerships and direct sales is structurally sound, but absent disclosed partner names, revenue mix or milestone visibility, future revenue predictability is weak. This lack of transparency increases execution risk around commercialization over the medium term.
Avecho Biotechnology Limited News
AVE FAQ
What was Avecho Biotechnology Limited’s price range in the past 12 months?
Avecho Biotechnology Limited lowest share price was <AU$0.01 and its highest was AU$0.01 in the past 12 months.
What is Avecho Biotechnology Limited’s market cap?
Avecho Biotechnology Limited’s market cap is AU$45.97M.
When is Avecho Biotechnology Limited’s upcoming earnings report date?
Avecho Biotechnology Limited’s upcoming earnings report date is Aug 31, 2026 which is in 92 days.
How were Avecho Biotechnology Limited’s earnings last quarter?
Avecho Biotechnology Limited released its earnings results on Feb 27, 2026. The company reported AU$0 earnings per share for the quarter, the consensus estimate of N/A by AU$0.
Is Avecho Biotechnology Limited overvalued?
According to Wall Street analysts Avecho Biotechnology Limited’s price is currently Overvalued.
Does Avecho Biotechnology Limited pay dividends?
Avecho Biotechnology Limited does not currently pay dividends.
What is Avecho Biotechnology Limited’s EPS estimate?
Avecho Biotechnology Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Avecho Biotechnology Limited have?
Avecho Biotechnology Limited has 3,830,448,200 shares outstanding.
What happened to Avecho Biotechnology Limited’s price movement after its last earnings report?
Avecho Biotechnology Limited reported an EPS of AU$0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Avecho Biotechnology Limited?
Currently, no hedge funds are holding shares in AU:AVE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Avecho Biotechnology Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:AVE Sentiment 90%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
-370.40%
Trailing 12-Months
Asset Growth
42.21%
Trailing 12-Months
Company Description
Avecho Biotechnology Limited
Avecho Biotechnology Limited, a biotechnology company, develops, produces, and sells products using its patented platform technology, Targeted Penetration Matrix (TPM) drug delivery system for the pharmaceutical, skin care, animal health, and nutrition industries. It offers TPM and Vital ET products for use in drug delivery and cosmetic formulations; and develops TPM/Oxymorphone and TPM/Oxycodone. The company's human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. It also provides non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals. The company has a collaboration with Lambert Initiative at the University of Sydney to conduct a study to examine whether topically applied cannabidiol can provide relief from symptoms of osteoarthritis. It serves customers in Australia, Switzerland, India, and internationally. The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited was incorporated in 1992 and is based in Clayton, Australia.
Technical Analysis
Living Cell Technologies
―
Immuron Limited
―
Noxopharm Ltd.
―
Chimeric Therapeutics Ltd.
―
Memphasys Ltd
―
Options Prices
Currently, No data available
---